We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Acasti Pharma Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, enhanced effic... Acasti Pharma Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery all which could help to increase treatment compliance and improve patient outcomes. Show more
false000144419200014441922024-02-122024-02-12 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section...
false000144419203-31Q320240001444192us-gaap:SellingAndMarketingExpenseMember2023-04-012023-12-310001444192us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-3000014441922023-09-242023-09-2400...
false000144419200014441922024-01-052024-01-05 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
false000144419200014441922023-12-112023-12-11 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.005 | 0.146198830409 | 3.42 | 3.45 | 3.37 | 63117 | 3.4005416 | CS |
4 | 0.005 | 0.146198830409 | 3.42 | 3.5 | 3.2629 | 33485 | 3.40212764 | CS |
12 | 0.705 | 25.9191176471 | 2.72 | 3.59 | 1.98 | 29572 | 3.02036284 | CS |
26 | 0.485 | 16.4965986395 | 2.94 | 3.59 | 1.98 | 28192 | 2.82990793 | CS |
52 | 0.8456 | 32.7828177095 | 2.5794 | 3.84 | 1.72 | 48599 | 2.88260545 | CS |
156 | -0.1948 | -5.38151279076 | 3.6198 | 17.6352 | 1.72 | 1797787 | 3.8006958 | CS |
260 | -2.635 | -43.4818481848 | 6.06 | 18.48 | 1.026 | 5006020 | 4.16072544 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions